WO2025027554 - HUMANIZED MUC1 ANTIBODY AND ANTIBODY DRUG CONJUGATE
National phase entry:
Publication Number
WO/2025/027554
Publication Date
06.02.2025
International Application No.
PCT/IB2024/057438
International Filing Date
31.07.2024
Title **
[English]
HUMANIZED MUC1 ANTIBODY AND ANTIBODY DRUG CONJUGATE
[French]
ANTICORPS MUC1 HUMANISÉS ET CONJUGUÉ ANTICORPS-MÉDICAMENT
Applicants **
SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
Inventors
DAMLE, Nitin Krishnaji
MEHRA, Vikas B
BEHERA, Adaitya Prasad
GUPTA, Shruti
KUMAR, Vinod P.
THAKER, Akhil
CHRUVATTIL, Ragithakumari
DAS, Argha
SAMANTA, Biswajit
SHAKTI, Jain
KUMAR, Nemmani
Priority Data
202321051338
31.07.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3504 | |
| EPO | Filing, Examination, Granting | 26431 | |
| Japan | Filing, Examination, Granting | 3230 | |
| South Korea | Filing, Examination, Granting | 4306 | |
| USA | Filing, Examination, Granting | 17390 |
Total:
54,861
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This invention relates to humanized MUC1 antibodies, antibody drug conjugates (ADCs) comprising such antibodies, and their use in treating disorders, such as cancer, especially where MUC1 is overexpressed.[French]
La présente invention concerne des anticorps MUC1 humanisés, des conjugués anticorps-médicament (ADC) contenant de tels anticorps, et leur utilisation dans le traitement de troubles, tels que le cancer, en particulier lorsque MUC1 est surexprimé.